Inaugural Bayer Co.Lab AdVenture Global Roadshow launches in Beijing: Connecting global capticals to empower biotech innovation
A quick description of what this article is about. This should set expectations and should typically not be longer than two rather short sentences.
- Innovation
- Strategy
Beijing, September 16, 2026 – The inaugural Bayer Co.Lab AdVenture Global Roadshow officially kicked off at BioPark, Beijing Economic-Technological Development Area (BDA) recently. The roadshow brought together 26 biotech residents and members of Bayer Co.Lab global community across China, the United States, Germany, Switzerland, Japan and South Korea. The biotech companies showcased their scientific breakthroughs and recent milestones, while engaging with more than 20 global investment firms as well as Bayer’s global R&D relevant experts, fostering efficient connections and exchange among innovators, investors and industry partners.
“Through the Bayer Co.Lab AdVenture Global Roadshow, we aim to faciliatate more biotech companies interactions with global capital and industry resources, accelerate their innovation journeys, and support their growth,” said Friedemann Janus, Ph.D., Senior Vice President, Head of Bayer Co.Lab, Regional BD&L and Divestitures, Bayer Pharmaceuticals. “Hosting the Bayer Co.Lab AdVenture Global Roadshow from China underscores the country’s role as one of the world’s most dynamic engines of biotech innovation, and reinforces Bayer’s long-term commitment to fostering China’s innovation ecosystem, connecting local innovators with global networks and opportunities, and supporting the development of innovation in China. Through open innovation and collaborations, we look forward to creating more opportunities for helping local innovation to benefit patients around the world.”
The Bayer Co.Lab AdVenture is Bayer Co.Lab’s first global platform dedicated to engagement with venture capital firms. It is designed to bridge startups and global investors, accelerating access to financing opportunities and strategic partnerships. Venture capital firms including Legend Capital, IDG Capital, Shanghai Industrial Investment Capital (SIIC), and Bayland Capital have already joined the platform and are actively supporting the development of Bayer Co.Lab resident companies.
As an integral part of Bayer’s global open innovation strategy, Bayer Co.Lab has established its sites in China, the United States, Japan and Germany. In nearly 40 months since its launch, Bayer Co.Lab has attracted close to 40 start-up residents and members globally and supported nearly USD 1.3 billion in cumulative financing. In China alone, residents have secured more than USD 300 million in financing after joining Bayer Co.Lab, helping advance more than ten investigational medicines to their next stage of development.
In China, Bayer Co.Lab operates sites in Zhangjiang, Shanghai, and BioPark in Beijing BDA. It currently hosts 13 resident companies,forming a diversified biotech innovation cluster spaning modalities and platform technologies, including small molecules, nucleic acids, cyclic peptides, antibody platforms, gene editing, AI-enabled discovery, and membrane proteins technologies. Leveraging Bayer’s global R&D expertise and open innovation network, Bayer Co.Lab continues to provide local innovators with access to industry resources, mentorship and international collaboration opportunities. Puhe BioPharma, a Bayer Co.Lab resident in China, entered into a global licensing agreement with Bayer for its oral small-molecule PRMT5 inhibitor targeting MTAP-deleted tumors. The program is currently undergoing global Phase II clinical development. This collaboration reflects Bayer’s ongoing commitment to working with innovation partners in China to accelerate the development of breakthrough therapies for patients worldwide.
Since its establishment in China two years ago, Bayer Co.Lab has continued to gain recognition in local innovation ecosystem. In April 2025, it was designated as the “Group Open Innovation Center” by Pudong government in Shanghai, and in August 2026, it was recognized as the “Foreign Enterprises Open Innovation Platform” by Shanghai Municipal government. These recognitions reflects Bayer Co.Lab’s active engagement in China’s biotech ecosystem and its continued contribtion to development of open innovatoin in China.
About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2025, the Group employed around 88,000 people and had sales of 45.6 billion euros. R&D expenses amounted to 5.8 billion euros. For more information, go to www.bayer.com.
Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.